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Abstract
Introduction One of the most common genetic aberrations
associated with breast cancer is the amplification and
overexpression of the ERBB2 proto-oncogene located at
chromosome 17, bands q12-21. The amplification/
overexpression occurs in 25 to 30% of all breast cancers. In
breast cancer, aneusomy of chromosome 17, either monosomy
or polysomy, is frequently observed by conventional
cytogenetics and fluorescence in situ hybridization (FISH). The
aim of this study was to discover whether or not numerical
aberrations on chromosome 17 have a correlation to the
amplification or overexpression of the ERBB2 gene and to
analyze their clinical implications in subgroups showing 2+ or
3+ positive scores by immunohistochemistry (IHC).
Methods We used FISH on a series of 175 formalin-fixed
paraffin-embedded breast carcinomas to detect ERBB2
amplification, using a dual-probe system for the simultaneous
enumeration of the ERBB2 gene and the centromeric region of
chromosome 17, as well as using IHC to detect overexpression.
We analyzed clinical and pathological variables in a subgroup of
patients with 2+ and 3+ IHC scores (147 patients), to describe
any differences in clinicopathological characteristics between
polysomic and non-polysomic cases with the use of the χ2 test.
Results We found 13% of cases presenting polysomy, and
three cases presented monosomy 17 (2%). According to the
status of the ERBB2 gene, instances of polysomy 17 were more
frequently observed in non-amplified cases than in FISH-
amplified cases, suggesting that the mechanism for ERBB2
amplification is independent of polysomy 17. Polysomy 17 was
detected in patients with 2+ and 3+ IHC scores. We found that
nodal involvement was more frequent in polysomic than in non-
polysomic cases (P = 0.046).
Conclusions The determination of the copy number of
chromosome 17 should be incorporated into the assesment of
ERBB2 status. It might also be helpful to differentiate a
subgroup of breast cancer patients with polysomy of
chromosome 17 and overexpression of ERBB2 protein that
probably have genetic and clinical differences.
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Introduction
Proto-oncogenes and tumor suppressor genes are two
classes of genes with central roles in the regulation of cell
growth. One of the most common genetic alterations asso-
ciated with human breast cancer is the amplification of the
ERBB2 proto-oncogene [1]. The ERBB2 gene located on
17q12-q21 encodes a 185 kDa transmembrane tyrosine
kinase receptor [2,3]. This protein is a member of the epi-
dermal growth factor receptor family [4] that comprises
four homologous receptors: HER1 (ERBB1), ERBB2
ER = estrogen receptor; FDA = US Food and Drug Administration; FISH = fluorescence in situ hybridization; H&E = hematoxylin/eosin; IHC = immu-
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(ERBB2), HER3 and HER4. These receptors are involved
in the activation of complex signaling pathways, essential
for cell survival and for the regulation of normal breast
growth and development [5-7]. Several studies performed
in various laboratories have demonstrated that 25 to 30%
of all breast and ovarian malignancies show the amplifica-
tion and overexpression of this gene [8,9]. Amplification of
the ERBB2 gene is found in more than 90% of cases that
have ERBB2 protein overexpression [10,11], but in normal
breast the expression of ERBB2 is due to a transcriptional
activation [12]. ERBB2 overexpression in women with both
node-positive [8,9] and node-negative [13] breast cancer
is associated with a poor prognosis, and several studies
have found a correlation between ERBB2 overexpression
and a shorter disease-free period and shorter overall sur-
vival [14,15].
ERBB2 overexpression and/or gene amplification is an
indication for trastuzumab (Herceptin; Genentech, South
San Francisco, CA, USA) therapy in patients with meta-
static breast cancer [16,17]. Clinical trials combining tras-
tuzumab and chemotherapy have been initiated, based on
preclinical data about potentially enhanced anti-tumor
activity when anti-ERBB2 antibodies were combined with
chemotherapeutic agents [18-20].
There are different methods available to evaluate ERBB2
status [21], although immunohistochemistry (IHC; for pro-
tein overexpression) and fluorescence in situ hybridization
(FISH; for gene amplification) offer several advantages,
because the aberration can be evaluated directly in malig-
nant cells taken from archival breast cancer specimens.
Reports of false-positive Herceptest cases led to sugges-
tions that Herceptests yielding a 2+ score should also be
studied by FISH [22]. Tubbs and colleagues [23], called for
the US Food and Drug Administration (FDA) to mandate
the retraction of the earlier accepted criteria for trastuzu-
mab therapy, namely that of Herceptests yielding a 2+
score, unless those cases were also confirmed by FISH.
The FDA-approved FISH assay, PathVysion (Vysis, Inc.,
Downers Grove, IL, USA), is a dual-probe system for the
simultaneous enumeration of the ERBB2 gene and the cen-
tromeric region of chromosome 17, defining ERBB2 ampli-
fication as a ratio of ERBB2 gene copies per chromosome
17 centromere [24]. Another FDA-approved FISH assay,
INFORM (Ventana Medical systems, Tucson, AZ, USA),
defines ERBB2 amplification as a mean absolute ERBB2
gene copy number of more than four spots per nucleus,
without centromere 17 correction. FISH with the PathVys-
ion probe and immunohistochemical assay with Herceptest
are highly concordant for cases showing 3+ IHC scores
and for negative cases, although the 2+ IHC score group
includes both ERBB2 amplified and non-amplified tumors,
showing a relatively high rate of discordance [25,26]. The
mechanisms for ERBB2 expression in non-amplified
tumors scored 2+ by IHC are unclear and may involve
increased gene dosage by chromosome 17 polysomy [27].
In breast carcinoma, chromosomal aneusomy – either
monosomy or polysomy – is frequently observed by con-
ventional cytogenetics and FISH [28,29]. Sauer and col-
leagues [30,31], found that an abnormal number of copies
of chromosome 17 have a low impact on ERBB2 gene and
its expression, but more studies are necessary to confirm
these results.
The aim of our study was to analyze the role of polysomy 17
in ERBB2 protein expression and its implication in ERBB2




This is a prospective analysis of 175 breast cancer
patients, consecutively treated at the Hospital del Mar of
Barcelona between August 2000 and August 2003.
Specimens
We studied specimens taken from 175 prospective cases
of human breast cancer. Overexpression was determined
by IHC, and amplification was studied by FISH.
The breast cancer specimens used in this study were fixed
with 4% buffered formalin, and the tissue was then embed-
ded in paraffin. Sections 4 to 6 µm thick were cut from the
tissue, mounted on silanized slides and then deparaffinized
in a xylene series, followed by immersion in 100% ethanol.
Then we serially sectioned a hematoxylin/eosin (H&E)-
stained tissue section, an IHC tissue section and a FISH
tissue section from each of the patient samples.
IHC assay
This method involved the application of primary ERBB2
antibody (rabbit anti-human ERBB2 oncoprotein; DakoCy-
tomation, Glostrup, Denmark) at 1:200 dilution. This anti-
body was evaluated with the dextran/peroxidase technique
(Dako Envision). We used negative and positive controls
for ERBB2 overexpression in all samples. The IHC tech-
nique was applied with an automated system (Tech Mate
500) after antigen retrieval at 110°C for 1 min in a wet auto-
clave. When FDA approved the Herceptest kit (DakoCyto-
mation) as a diagnostic method to detect ERBB2
overexpression, we began to use it. As a single institution,
we observed an excellent correlation between these two
IHC detection systems.
Membrane staining was interpreted as ERBB2 oncoprotein
expression. To evaluate the immunostaining for ERBB2
antibody, we considered the intensity and type ofAvailable online http://breast-cancer-research.com/content/7/2/R267
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membrane expression. Expression was recorded as fol-
lows: score 0, negative staining; score 1, local positivity
and incomplete membrane staining; score 2, moderate,
complete membrane staining; score 3, strong, complete
membrane staining.
FISH assay
The Pathvysion probe was used. This probe consists of two
different probes, one with the centromeric α-satellite
probe, specific for chromosome 17 (Spectrum green), and
a locus-specific probe from the ERBB2 gene (Spectrum
orange). The probe was provided denatured, in single-
stranded DNA.
Deparaffinized tissue sections were treated with 0.2 M HCl
and then with sodium thiocyanate, to eliminate salt precipi-
tates. Pretreated slides were incubated for 10 min in a solu-
tion of proteinase K at 37°C. The slides were then postfixed
in buffered formalin.
Pretreated tissue sections and probes were denatured at
78°C for 5 min and hybridized overnight at 37°C on a hot-
plate (Hybrite chamber; Vysis). Washes were performed
for 2 min at 72°C in a solution of 2 × SSC/0.3% Nonidet
P40. Tissue sections were counterstained with 10 µl of
4,6-diamino-2-phenylindole (DAPI counterstain; Vysis).
Results were analyzed in a fluorescent microscope (Olym-
pus BX51) with the Cytovysion software (Applied Imaging,
Santa Clara, CA, USA). Tissue sections were scanned at
low magnification (×100) with DAPI excitation to localize
those areas where histopathological characteristics had
been established by examining a serially sectioned H&E-
stained tissue section from the same patient.
Table 1
Correlation of chromosomal aneusomy with clinicopathological parameters
Parameter Total Disomy Polysomy Monosomy
Stage
I3 9 3 6 3 0
II 46 35 11 0
III 35 28 5 2
I V 7601
Nodal status
pN- 35 29 5 1
pN+ 113 99 12 2
HG
I1 6 1 5 1 0
II 55 42 12 1
III 47 39 6 2
ER
-6 0 5 0 9 1
+ 8 57 11 2 2
PgR
- 8 77 21 2 3
+ 5 84 81 0 0
p53
- 8 77 21 4 1
+5 6 8 4 6 2
Relapse
No 110 94 14 2
Yes 36 27 8 1
The mean age of patients was 62 years (range 30 to 94). ER, estrogen receptor; HG, histological grade; PgR, progesterone receptor.Breast Cancer Research    Vol 7 No 2    Salido et al.
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ERBB2 amplification was calculated by a ratio dividing the
most frequent value for ERBB2 spots per nucleus by the
most frequent value of chromosome 17 centromere spots
per nucleus. A minimum of 60 nuclei were scored. Amplifi-
cation of ERBB2 gene was considered when the ratio was
2 or more, in accordance with the manufacturer's recom-
mended scoring system. We considered polysomy 17
when the cells had three or more copy numbers of centro-
meres for chromosome 17 per cell.
Statistical analysis
A total of 147 patients with 2+ and 3+ IHC scores out of
175 of the complete cohort were analyzed, ensuring that all
the polysomies of chromosome 17 were detected in this
subgroup of patients. Table 1 describes the following clin-
Table 2
Polysomy 17 according to immunohistochemical scoring and fluorescence in situ hybridization analysis
Polysomy 17 Non-polysomy 17
IHC score FISH normal FISH amplified Polysomy 17 (%) FISH normal FISH amplified
0 0/8 0/0 0 8/8 0/0
1+ 0/20 0/0 0 20/20 0/0
2+ 13/66 0/12 17 53/66 12/12
3+ 1/1 8/68 15 0/1 60/68
Total 14/95 (15%) 8/80 (10%) 13 81/95 (85%) 72/80 (90%)
FISH, fluorescence in situ hybridization; IHC, immunohistochemistry.
Table 3
Concordance analysis using the χ2 test between the presence and absence of polysomy 17 and clinicopathological variables in a 
subgroup of 2+/3+ IHC patients
Parameter Non-polysomy (%) Polysomy (%) P
HG
I 15.6 5.3
II 43.8 63.2 0.243
III 40.6 31.6
Nodal status
pN- 61.3 35.3 0.046
pN+ 38.7 64.7
ER
- 41.7 40.9 0.947
+ 58.3 59.1
PgR
- 60 54.5 0.632
+4 0 4 5 . 5
p53
- 61 63.6 0.817
+3 9 3 6 . 4
Relapse
No 77 63.6 0.181
Yes 23 36.4
ER, estrogen receptor; HG, histological grade; PgR, progesterone receptor.Available online http://breast-cancer-research.com/content/7/2/R267
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icopathological parameters: clinical stage, nodal status,
histological grade, estrogen receptor (ER), progesterone
receptor (PgR), p53 protein and relapse of the disease,
and age description. We performed a concordance analy-
sis using the χ2 test between prognostic variables and the
presence or absence of polysomy 17 to detect any differ-
ences between polysomic and non-polysomic subgroups.
Results
To validate the FISH technique, in a first screening step we
performed FISH on 50 specimens that represented all of
the immunohistochemical subgroups (0, 1+, 2+ and 3+).
For subsequent specimens we performed FISH on 2+ and
3+ IHC subgroups. The exclusion of the subgroups with
scores of 0 and 1+ was based on our previous finding that
none of those cases had ERBB2 gene amplification [25].
This selection process resulted in the under-representation
of IHC-negative and 1+ specimens for the FISH assay and
a high proportion of 2+/3+ cases.
Among the 175 specimens studied by IHC and FISH, 22
cases showed polysomy of chromosome 17 (13%), and
three cases presented monosomy (2%) (Table 2). Of the
175 cases, 147 showed an IHC score of 2+ or 3+. The dis-
tribution of chromosome 17 copy numbers in this 2+/3+
subgroup is illustrated in Fig. 1. Most of the cases with
polysomy 17 had four copies of chromosome 17 per cell.
We observed that all cases with polysomy of chromosome
17 had an IHC score of 2+ or 3+. Thirteen of 22 cases with
polysomy revealed an IHC score of 2+, and the remaining
9 cases had an IHC score of 3+. In a subgroup of 78
patients having IHC scores of 2+, 13 of 78 (17%) showed
polysomy of chromosome 17 with increased ERBB2 gene
copies, but without gene amplification. In a subgroup hav-
ing IHC scores of 3+, 9 of 69 cases (15%) presented poly-
somy 17. In patients with monosomy of chromosome 17,
two cases presented IHC scores of 2+, and one presented
an IHC score of 3+, without ERBB2 gene amplification.
According to ERBB2 gene status, all cases with polysomy
and 2+ IHC scores were considered to be normal for
ERBB2 gene amplification (the ratio was 2 or less). Of the
cases considered normal by FISH, 15% presented polys-
omy 17, and 10% of the amplified cases showed amplifica-
tion and polysomy 17 simultaneously (Table 2). Within the
subgroup having scores of 3+ and polysomy, only one case
presented non-amplification of the ERBB2 gene.
We compared the polysomic subgroup with the non-polys-
omic subgroup, to determine whether there were differ-
ences in the clinicopathological features. After clinical
analysis of the 147 patients who were 2+/3+ by IHC, we
found that nodal involvement was significantly associated
with polysomy 17 (P = 0.046). Furthermore, patients with
polysomy 17 also showed a non-statistical trend toward
relapse (P = 0.181). No statistically significant correlation
was observed between histological grade, ER, PgR and
p53 variables and the polysomy of chromosome 17 (Table
3).
Discussion
In our study, 175 cases diagnosed as invasive breast can-
cer were examined to determine the frequency of chromo-
some 17 polysomy in different ERBB2 IHC subgroups. In
our series we found 22 specimens with polysomy 17
(13%) and three cases with monosomy 17 (2%). In a series
from Wang and colleagues [31], aneusomy was very com-
mon (more than 50%), but only 10 of 189 cases (5%)
showed high polysomy (at least 3.76 signals of centromere
17 per cell). Series from Watters and colleagues [32] pre-
sented a high proportion of aneusomy 17 (54%); most of
those presented polysomy, but the highest proportion fell
into the 2.00 to 3.00 chromosome 17 copy numbers cate-
gory. In those two series [31,32], they considered polys-
omy with a mean chromosome copy number near to
disomy. The reason for the discordance with our series
(13% versus 50%) could be explained by the consideration
of polysomy 17 when the cells had three or more copy num-
bers of centromeres for chromosome 17 per cell, in agree-
ment with other authors [22,26,27,29].
Cases with polysomy 17 could be considered to be ampli-
fied at a low level by absolute criteria, but they had to be
classified as non-amplified when the number of ERBB2
copies was corrected for the number of chromosome 17
centromeres. FISH, using the dual probe for the ERBB2
gene and the centromere of chromosome 17, offers the
greatest resolution in detecting alterations of the ERBB2
gene in breast tumors because it allows true amplification
to be differentiated from polysomy 17. The FISH method is
less affected by tissue variables than the IHC method, and
it has emerged as the gold standard for the assessment of
ERBB2 status in breast cancer.
Figure 1
Distribution pattern of polysomy 17 in our series of 147 patients stud- ied by fluorescence in situ hybridization Distribution pattern of polysomy 17 in our series of 147 patients stud-
ied by fluorescence in situ hybridization.Breast Cancer Research    Vol 7 No 2    Salido et al.
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We observed polysomy 17 in non-amplified cases more
frequently than in FISH amplified cases (15% versus 10%),
suggesting that the mechanism for amplification of the
ERBB2 gene is independent of polysomy.
In our series, polysomy 17 was frequently associated with
a 2+ and 3+ IHC score. We had 13 of 22 polysomic cases
that showed IHC 2+ scores with FISH-negative results. In
contrast, other authors [33,34] found that the incidence of
polysomy 17 in 2+ non-amplified cases was similar to the
incidence of polysomy 17 in IHC-negative cases, suggest-
ing that weak overexpression (2+) without gene amplifica-
tion is not secondary to chromosome 17 polysomy. Our
findings support the concept that polysomy 17 is a genetic
aberration independent of IHC status but that it might have
a role in ERBB2 expression in weakly positive (2+) and in
strongly positive (3+) cases. It is probable that there are
non-amplified cases analyzed by FISH with false positive
IHC (2+) scores as a result of polysomy 17. Polysomy 17,
in the absence of ERBB2 amplification, would result in an
increase in protein production to such level that it might be
IHC stained as a positive result (2+).
We identified only one such case, IHC scored at 3+, non-
amplified by FISH, and showing polysomy 17. It is reason-
able that the copy number of chromosome 17 was associ-
ated with an increased level of ERBB2 protein but not with
ERBB2 gene amplification. With regard to this case, we
are in agreement with Lal and colleagues [33] and Varsh-
ney and colleagues [34], who suggested that the findings
of strongly positive IHC staining (3+) without gene amplifi-
cation might be due, in part, to the increased copy numbers
of chromosome 17, resulting in ERBB2 overexpression.
In our study of 147 patients having tumors with 2+/3+ IHC
scores, we found a statistical association between polys-
omy 17 and nodal involvement, and we observed that this
subgroup of patients had a trend towards relapse more fre-
quently than the non-polysomic cases. Only a few studies
have focused on the analysis of the prognostic value of
chromosome 17 aneusomy, and specifically on polysomy
17. In a large series from Watters and colleagues [32],
abnormalities in chromosome 17 copy numbers were asso-
ciated with grade III carcinomas and ER negativity, but they
were without significant impact on survival. Other studies
proposed that aneusomy of chromosome 17 is associated
with poor prognostic factors in breast cancer [30].
Conclusions
Breast tumors scoring at 2+ or 3+ by IHC should be ana-
lyzed by FISH for ERBB2, preferably with a dual-probe sys-
tem capable of detecting aberrations in chromosome 17
that could affect ERBB2 expression. The accurate meas-
urement of chromosome 17 polysomy might also be helpful
in determining subgroups of patients with genetic and clin-
ical differences, which would permit their inclusion in future
clinical trials.
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